The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBioquell Share News (BQE)

  • There is currently no data for BQE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Bioquell surges on offer from Bill Gates-backed Ecolab

Fri, 30th Nov 2018 08:49

(Sharecast News) - Bioquell shares surged on Friday as it agreed to be bought by US hygiene company Ecolab for £140.5m.Under the terms of the offer, Bioquell shareholders will be entitled to receive 590p in cash for each of their shares. This represents a premium of about 40.5% to the closing price on Thursday and 23.1% to the three-month volume-weighted average closing price.Ecolab provides water, hygiene and energy technologies and services. It delivers comprehensive solutions and on-site services to promote safe food, maintain clean environments, optimise water and energy use and improve operational efficiencies for customers in food, healthcare, life sciences, hospitality, energy and industrial markets in more than 170 countries around the world.Bioquell, meanwhile, manufactures infection control, bioburden control and environmental filtration technology.Bioquell said in a statement that its directors, who were advised by N+1 Singer, consider the terms of the offer to be "fair and reasonable" and intend to recommend that shareholders vote in its favour at the next general meeting.Executive chairman Ian Johnson said: "As part of Ecolab, Bioquell will be able to drive faster strategic growth in both life sciences and healthcare markets leveraging Ecolab's extensive global footprint."The Bioquell directors believe the strategic fit is extremely strong and that the combination offers employees and customers a highly desirable opportunity to continue Bioquell's successful tradition."Ecolab's offer provides Bioquell shareholders with a certain cash exit at a premium to the price at which the company's shares have traded recently and is supported by Bioquell shareholders representing, in aggregate, approximately 55.10% of the existing issued ordinary share capital of Bioquell."At 0845 GMT, Bioquell shares were up 37% to 575.10p.
More News
14 May 2014 15:15

UK Earnings, Trading Statements Calendar - Week Ahead

UK Earnings, Trading Statements Calendar 
Read more
13 May 2014 15:30

UK AGM, EGM Calendar - Week Ahead

UK AGM, EGM Calendar
Wednesday, May 14
Read more
13 May 2014 15:30

UK Earnings, Trading Statements Calendar - Week Ahead

UK Earnings, Trading Statements Calendar 
Read more
13 May 2014 05:11

UK Earnings, Trading Statements Calendar - Week Ahead

UK Earnings, Trading Statements Calendar 
Read more
13 May 2014 05:11

UK AGM, EGM Calendar - Week Ahead

UK AGM, EGM Calendar
Tuesday, May 13
Read more
12 May 2014 15:16

UK Earnings, Trading Statements Calendar - Week Ahead

UK Earnings, Trading Statements Calendar 
Read more
12 May 2014 15:16

UK AGM, EGM Calendar - Week Ahead

UK AGM, EGM Calendar
Tuesday, May 13
Read more
2 Apr 2014 11:31

DIRECTOR DEALINGS: Bioquell Finance Director Buys Shares

LONDON (Alliance News) - Bioquell PLC Wednesday said Finance Director Michael Roller bought 19,245 shares at a price of 129.9 pence per share. Following this transaction, Roller owns 19,245 shares, representing less than 0.05% of the company's issued share capital. Shares in the medic

Read more
18 Mar 2014 11:16

Bioquell Raises Total Dividend, Pretax Profit Declines

LONDON (Alliance News) - Biotechnology company Bioquell PLC Tuesday raised its total dividend for 2013, as pretax profit declined, hit by higher oeprating expenses and sales costs. Bioquell posted a total dividend of 3.3 pence, up from 3.06 pence in the previous year. The company post

Read more
18 Mar 2014 08:58

Tuesday broker round-up UPDATE

Antofagasta: Investec places its target price (prev.: 753p) under review, while leaving its sell recommendation unchanged. Ashtead Group: Credit Suisse raises target price from 1000p to 1100p and stays with its outperform rating. UBS increases target price from 875p to 1020p retaining its buy recom

Read more
18 Mar 2014 06:31

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
17 Mar 2014 15:51

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
17 Mar 2014 06:12

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
14 Mar 2014 16:14

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
14 Mar 2014 06:29

UK Earnings, Trading Statements Calendar - Week Ahead

Read more

Quickpicks are a member only feature

Login to your account